BCLI.OQBBrainstorm Cell Therapeutics INC
10-Q: Brainstorm Cell Therapeutics Q2 2025: Nasdaq Delisting, ALS Trial Progress
Sentiment:
Quarterly Report
Brainstorm Cell Therapeutics reported Q2 2025 financial results, detailing its Nasdaq delisting, ongoing clinical progress for NurOwn in ALS, and significant capital raising activities amidst continued operating losses.
Capital raiseRaised $4.035 million net from the August 9, 2021 At-the-Market (ATM) offering during the six months ended June 30, 2025.Generated $1.769 million from the exercise of warrants during the six months ended June 30, 2025.Settled $450,000 in outstanding accounts payable to a supplier through a debt-for-equity swap by issuing 281,250 shares of common stock.Entered into an inducement offer on March 31, 2025, with a holder to exercise 1,381,383 existing warrants, resulting in the issuance of new unregistered warrants equal to 200% of the exercised shares.Repaid approximately $1.1 million of short-term loans between November 2024 and May 2025, with $100,000 remaining outstanding from a March 6, 2025 loan due March 6, 2026.Stated that substantial additional financing will be needed in the future to fund operations, conduct the Phase 3b trial, and commercialize NurOwn.
Worse than expectedDelisted from Nasdaq due to non-compliance with minimum shareholder equity requirement.Advisory Committee voted overwhelmingly against NurOwn's effectiveness for ALS, leading to BLA withdrawal.Identified a material weakness in internal control over financial reporting.Increased cash used in operating activities for the six months ended June 30, 2025.Facing multiple shareholder lawsuits.
Summary
- Reported a net loss of $2.903 million for the three months ended June 30, 2025, compared to $2.541 million for the same period in 2024.
- Net loss for the six months ended June 30, 2025, was $5.767 million, an improvement from $5.942 million for the same period in 2024.
- Cash and cash equivalents increased to $824,000 as of June 30, 2025, from $187,000 at December 31, 2024.
- Delisted from The Nasdaq Stock Market on July 18, 2025, due to non-compliance with the minimum shareholder equity requirement, and now trades on the OTCQB Venture Market.
- Received FDA clearance on May 19, 2025, to initiate its Phase 3b clinical trial of NurOwn for ALS, following a Special Protocol Assessment (SPA) agreement with the FDA on April 9, 2024.
- Identified a material weakness in internal control over financial reporting related to short-term loan management.
- Faces multiple shareholder lawsuits, including a securities class action and derivative actions, related to NurOwn's ALS approval process.
Sentiment
Score: 3
Explanation: While there is progress on the Phase 3b trial design and some financial improvements in cash balance and reduced liabilities, the Nasdaq delisting, ongoing significant losses, and the prior negative FDA advisory committee vote for NurOwn in ALS represent major setbacks and risks. The material weakness in internal controls and ongoing lawsuits further dampen sentiment, indicating significant operational and financial challenges despite clinical efforts.
Positives
- FDA cleared initiation of Phase 3b clinical trial for NurOwn in ALS on May 19, 2025.
- Received Special Protocol Assessment (SPA) agreement from FDA on April 9, 2024, validating the design for the Phase 3b trial of NurOwn in ALS.
- Achieved alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects for NurOwn's Phase 3b clinical trial on June 26, 2024.
- Cash and cash equivalents increased to $824,000 as of June 30, 2025, from $187,000 at December 31, 2024.
- Total current assets increased to $1,515,000 as of June 30, 2025, from $385,000 at December 31, 2024.
- Total liabilities decreased to $8,623,000 as of June 30, 2025, from $9,596,000 at December 31, 2024.
- Net loss for the six months ended June 30, 2025, decreased to $5.767 million from $5.942 million in the prior year period.
- Basic and diluted net loss per share improved to $(0.77) for the six months ended June 30, 2025, from $(1.35) in the prior year period.
- Successfully raised $4.035 million net from its At-the-Market (ATM) offering during the six months ended June 30, 2025.
- Exercised warrants generated $1.769 million in proceeds during the six months ended June 30, 2025.
- Secured a new patent allowance from the USPTO for its exosome technology on December 3, 2024, providing protection until April 10, 2039.
- Stockholders approved an increase of 2,000,000 shares to the shared pool for the 2014 Stock Incentive Plan and 2014 Global Share Option Plan on June 25, 2025.
Negatives
- Delisted from The Nasdaq Stock Market on July 18, 2025, due to non-compliance with the minimum shareholder equity requirement.
- Common stock now trades on the OTCQB Venture Market, which could limit liquidity and price.
- Incurred a net loss of $2.903 million for the three months ended June 30, 2025, an increase from $2.541 million for the same period in 2024.
- Operating loss for the six months ended June 30, 2025, increased to $5.662 million from $5.456 million in the prior year period.
- Cash used in operating activities increased to $5.133 million for the six months ended June 30, 2025, from $4.746 million in the prior year period.
- Accumulated deficit increased to $232.403 million as of June 30, 2025.
- Identified a material weakness in internal control over financial reporting related to short-term loan management.
- Faces multiple putative securities class action and derivative lawsuits from shareholders.
- An Advisory Committee voted against NurOwn demonstrating substantial evidence of effectiveness for mild to moderate ALS (17 no, 1 yes, 1 abstention) on September 27, 2023, leading to the withdrawal of the BLA.
- The August 9, 2021 ATM program may no longer be available for use due to Nasdaq delisting.
Risks
- Delisting from Nasdaq and trading on OTCQB Venture Market could limit liquidity and price of common stock, reduce trading activity, limit analyst coverage, and decrease ability to issue additional securities or obtain financing.
- Inability to raise additional capital on timely or acceptable terms, or at all, which raises substantial doubts about the ability to continue as a going concern.
- Ongoing operating losses and expectation to continue incurring losses for the near-term.
- Outcomes of putative securities class action and derivative lawsuits filed by shareholders, with potential for more derivative lawsuits.
- Material weakness identified in internal control over financial reporting related to short-term loans, which if not remediated, could result in material misstatements.
- Adverse macroeconomic conditions, including fears concerning inflation, rising interest rates, volatile market conditions, and geopolitical instability (e.g., conflicts involving Ukraine/Russia and Israel/surrounding regions), could adversely affect business and ability to raise funding.
- Unsecured indebtedness from short-term loans could adversely affect financial condition and results of operations if unable to secure sufficient cash flows to service debt.
- Inability to obtain regulatory approval for NurOwn treatment candidate or successfully commercialize it.
- Success of product development programs and research, regulatory and personnel issues, and ability to develop a global market for services.
- Ability to secure and maintain research institutions to conduct clinical trials.
- Ability to generate significant revenue and achieve profitability.
- Ability of NurOwn to achieve broader acceptance as a treatment option for ALS, PMS, AD, or other neurodegenerative diseases.
- Ability to manufacture and commercialize NurOwn treatment candidate.
- Obtaining patents that provide meaningful protection and protecting intellectual property from infringement.
- Competition and market developments.
- Health reform legislation, demand for services, currency exchange rates, and product liability claims and litigation.
Future Outlook
The company expects to continue incurring operating losses from clinical development and regulatory activities, resulting in negative cash flow. Substantial additional financing will be required to fund operations, conduct the planned Phase 3b trial for NurOwn in ALS, commercialize NurOwn, and support future trials for other indications. The ability to raise capital on acceptable terms is uncertain, especially after Nasdaq delisting.
Management Comments
- Our highest priority is to obtain regulatory approval of NurOwn for ALS.
- We are also strategically focused on fully executing the clinical development of NurOwn in PMS, reviewing the optimal approach in AD and will consider the best course of action based on recent scientific and regulatory insights.
- Brainstorm remains committed to the ALS Community and is actively exploring the next steps in support of NurOwn, including publication of emerging clinical data and development of a protocol for an additional clinical study.
- The SPA agreement with the FDA validates the clinical trial protocol and statistical analysis of the planned Phase 3b trial of NurOwn, demonstrating the Company's adequacy in addressing objectives that support a future BLA in ALS.
- The decision to withdraw the BLA was coordinated with FDA and is viewed by FDA as a withdrawal without prejudice.
Industry Context
Brainstorm Cell Therapeutics operates in the highly specialized and capital-intensive biotechnology sector, focusing on autologous stem cell therapies for neurodegenerative diseases like ALS, PMS, and Alzheimer's. The company's strategy of developing a proprietary cell therapy platform (NurOwn) and exploring exosome-based technologies aligns with broader industry trends towards advanced therapies and personalized medicine. However, the significant regulatory hurdles, as evidenced by the FDA's previous refusal to file and the advisory committee's negative vote for NurOwn in ALS, highlight the inherent challenges in bringing novel treatments to market for complex neurological conditions. The company's delisting from Nasdaq to OTCQB reflects the financial pressures and market skepticism often faced by development-stage biotechs without commercialized products, especially after regulatory setbacks.
Comparison to Industry Standards
- The filing does not provide specific comparable companies, projects, or results for direct quantitative comparison.
- The company's continued operating losses and reliance on financing are typical for a clinical-stage biotechnology company that has not yet commercialized a product.
- The FDA's rigorous review process, including refusal to file letters and advisory committee votes, is standard for novel therapies, particularly for severe diseases like ALS, and reflects the high bar for demonstrating substantial evidence of effectiveness.
- The move from Nasdaq to OTCQB is a common outcome for companies that fail to meet listing requirements, indicating a lower tier of market liquidity and investor visibility compared to major exchanges.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Plan Amendment | Stockholders approved amendments to the 2014 Stock Incentive Plan and 2014 Global Share Option Plan to increase the shared pool of shares available for issuance by 2,000,000 shares, from 906,666 to 2,906,666 shares. | 2025-06-25 | Increases the pool of shares for stock-based compensation, potentially aiding in attracting and retaining personnel but also leading to further dilution for existing shareholders. |
Legal Proceedings
- Putative securities class action complaint (Sporn v. Brainstorm Cell Therapeutics Inc., et al.) filed November 1, 2023, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act related to NurOwn for ALS and allegedly inflated stock price between February 18, 2020, and September 27, 2023.
- Four consolidated derivative action complaints (In Re Brainstorm Cell Therapeutics, Inc. Derivative Litigation) filed between February 14, 2024, and April 12, 2024, asserting state law claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and Section 14(a) violations against officers and directors, seeking monetary damages and disgorgement of performance-based compensation.
- Breach of contract lawsuit by 3D Communications, LLC (3D Communications, LLC v. Brainstorm Cell Therapeutics, Inc.) filed November 22, 2024, for allegedly unpaid invoices related to consulting services.
Related Party Transactions
- Entered into a loan agreement with a related party for a principal amount of $120,000 on November 4, 2024, which was repaid on May 21, 2025.
- Except for transactions and balances related to loans and share-based compensation to officers and directors, no other related party transactions were disclosed for the six months ended June 30, 2025.
Stakeholder Impact
- Shareholders are directly impacted by the Nasdaq delisting and move to OTCQB, which could reduce liquidity and share price. They also face potential for significant dilution from future capital raises and are affected by ongoing litigation which could result in damages or disgorgement.
- Employees and Directors benefit from increased share pool for stock-based compensation, aiding retention and incentivization.
- The ALS Community may potentially benefit in the future from the planned Phase 3b clinical trial of NurOwn, offering hope for a new treatment option.
- Creditors are impacted by the company's ability to service its remaining short-term debt and overall financial health.
- One supplier (3D Communications, LLC) is involved in a breach of contract lawsuit over unpaid invoices.
Next Steps
- Initiate Phase 3b clinical trial of NurOwn for ALS following FDA clearance.
- Continue exploring next steps for NurOwn in ALS, including publication of emerging clinical data.
- Fully execute clinical development of NurOwn in Progressive Multiple Sclerosis (PMS).
- Review optimal approach for NurOwn in Alzheimer's Disease (AD) based on scientific and regulatory insights.
- Continue research and development for NurOwn and MSC-NTF derived Exosomes in various neurodegenerative disorders, neurodegenerative eye disease, and acute respiratory distress syndrome (ARDS).
- Remediate the identified material weakness in internal control over financial reporting.
- Raise substantial additional financing to fund operations, conduct the Phase 3b trial, commercialize NurOwn, and support future trials.
- Defend against ongoing securities class action and derivative lawsuits.
- Negotiate a contract with a leading manufacturing contract development organization (CDMO).
Key Dates
| Date | Description |
|---|---|
| 2000-09-22 | Company inception. |
| 2004-10-01 | Formed wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd. (BCT) in Israel. |
| 2006-11-15 | Incorporated in the State of Delaware. |
| 2011-06-01 | Initiated first-in-human Phase 1 safety and efficacy trial of NurOwn in ALS patients. |
| 2016-01-01 | Results of two completed Phase 1/2 and Phase 2 open label trials published in JAMA Neurology. |
| 2017-07-01 | Awarded $15.9 million grant from California Institute for Regenerative Medicine (CIRM). |
| 2018-06-21 | BCT formed wholly-owned subsidiary Advanced Cell Therapies Ltd. in Israel. |
| 2018-10-01 | DFCI commenced manufacturing NurOwn for Phase 3 ALS clinical study. |
| 2018-12-15 | FDA approved IND to conduct Phase 2 open-label trial of NurOwn in PMS. |
| 2019-07-01 | Brainstorm management invited to special high-level meeting with senior FDA management. |
| 2019-10-01 | Phase 3 ALS clinical trial completed enrollment of enriched patient population. |
| 2019-11-14 | Awarded $495,330 grant from the National Multiple Sclerosis Society (NMSS). |
| 2019-12-18 | Clinical trial independent Data Safety Monitoring Board (DSMB) for U.S. Phase 2 PMS study completed first interim analysis. |
| 2019-12-01 | Results of Phase 2 ALS Study published in Neurology. |
| 2020-02-11 | Held high-level meeting with FDA to discuss potential NurOwn regulatory pathways for approval in ALS. |
| 2020-06-09 | ALS Association and I AM ALS awarded a combined grant of $500,000. |
| 2020-06-24 | Announced new clinical program focused on development of NurOwn as a treatment for AD. |
| 2020-10-22 | Announced partnership with Catalent to manufacture NurOwn. |
| 2020-11-17 | Announced top-line data from Phase 3 ALS trial. |
| 2020-12-01 | Received final payment of $462,390 from CIRM grant. |
| 2020-12-14 | Announced NurOwn Expanded Access Program (EAP) for ALS patients. |
| 2021-01-20 | Peer-reviewed publication of preclinical study on MSC-NTF (NurOwn) exosomes in ARDS mouse model. |
| 2021-02-09 | Announced feedback from Type-C Meeting with FDA on future NurOwn manufacturing plans. |
| 2021-02-22 | Announced high-level FDA feedback on NurOwn ALS clinical development program. |
| 2021-03-24 | Announced positive top-line data from Phase 2 study evaluating NurOwn as a treatment for PMS. |
| 2021-08-09 | Entered into Amended and Restated Distribution Agreement for ATM offering of up to $100,000,000. |
| 2021-08-01 | Clinical trial independent DSMB for U.S. Phase 2 PMS study issued end-of-study statement. |
| 2021-10-14 | Presented detailed summary of PMS study outcomes at 37th Congress of ECTRIMS. |
| 2021-10-19 | Presented poster titled 'Therapeutic Benefits of MSC-NTF (NurOwn) Exosomes in Acute Lung Injury Models' at NYSCF 2021 Virtual Meeting. |
| 2021-12-07 | Catalent announced completion of technology transfer for NurOwn manufacturing at Houston facility. |
| 2021-12-27 | Announced plans for a dosing extension of NurOwn for participants who completed the EAP. |
| 2022-05-04 | Made presentation titled 'MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived from nave MSCs' at ISCT 2022 Meeting. |
| 2022-05-26 | Presented poster titled 'Therapeutic effect of MSC-NTF exosomes in experimental bleomycin-induced lung injury' at ISEV 2022 Annual Meeting. |
| 2022-06-02 | Market Value of Listed Securities (MVLS) fell below Nasdaq minimum requirement. |
| 2022-08-12 | New clinical analyses of NurOwn's Phase 3 clinical trial in ALS published, leading to data correction. |
| 2022-08-15 | Announced decision to submit a Biologics License Application (BLA) to FDA for NurOwn for ALS. |
| 2022-08-21 | Formed wholly-owned subsidiary in Delaware, Brainstorm Cell Manufacturing LLC. |
| 2022-09-09 | Filed BLA to FDA for NurOwn for the treatment of ALS. |
| 2022-09-15 | Published findings from PMS Phase 2 study in Multiple Sclerosis Journal. |
| 2022-11-10 | Received refusal to file (RTF) letter from FDA regarding BLA. |
| 2022-12-12 | Submitted Type A meeting request with FDA to discuss RTF letter. |
| 2022-12-27 | FDA granted Type A meeting to discuss RTF letter. |
| 2023-01-11 | Type A Meeting with FDA held to discuss RTF letter. |
| 2023-02-06 | Notified FDA of decision to request filing NurOwn BLA for ALS over Protest. |
| 2023-02-07 | Received confirmation from FDA that BLA was re-filed. |
| 2023-02-09 | Received FDA Type A meeting minutes. |
| 2023-03-07 | Submitted amendment to BLA responding to majority of RTF letter items. |
| 2023-03-22 | Received written feedback from FDA confirming decision to grant an ADCOM for NurOwn BLA for ALS. |
| 2023-03-27 | Announced FDA will hold an ADCOM to discuss BLA for NurOwn for ALS. |
| 2023-06-02 | Australian Patent Office accepted Application No. 2019252987 for exosome technology. |
| 2023-06-06 | Advisory committee meeting scheduled for September 27, 2023. |
| 2023-07-17 | Entered into Securities Purchase Agreement for sale of 270,270 shares and warrants for $7.5 million gross proceeds. |
| 2023-07-19 | Offering closed for 270,270 shares and warrants. |
| 2023-08-22 | Israel Patent Office accepted Application No. 277447, titled 'Cell-Type Specific Exosomes and Use Thereof'. |
| 2023-09-22 | Submitted amendment to BLA to revise indication to NurOwn for mild to moderate ALS. |
| 2023-09-27 | Advisory Committee voted against NurOwn demonstrating substantial evidence of effectiveness for mild to moderate ALS (17 no, 1 yes, 1 abstention). |
| 2023-10-18 | FDA invited Company to request expedited meeting to discuss path forward for NurOwn in ALS. |
| 2023-10-18 | Announced BLA for NurOwn would be withdrawn. |
| 2023-11-01 | First securities class action lawsuit filed (Sporn v. Brainstorm Cell Therapeutics Inc., et al.). |
| 2023-11-03 | BLA for NurOwn withdrawn (without prejudice). |
| 2023-11-20 | FDA granted meeting to discuss regulatory path forward for NurOwn in ALS. |
| 2023-11-22 | 3D Communications, LLC filed breach of contract lawsuit against the Company. |
| 2023-12-06 | Meeting with FDA held to discuss regulatory path forward for NurOwn. |
| 2023-12-07 | Announced completion of productive meeting with FDA to discuss NurOwn and plans for SPA. |
| 2023-12-26 | Announced European grant for NurOwn, alongside Australian and Israeli allowances for NurOwn exosomes. |
| 2024-01-14 | Deadline to regain compliance with Nasdaq's MVLS Requirement. |
| 2024-01-15 | Nasdaq notified failure to regain MVLS compliance. |
| 2024-01-21 | Submitted request to appeal Nasdaq's delisting determination. |
| 2024-02-14 | First derivative action lawsuit filed (Porteous v. Lebovits, et al.). |
| 2024-02-15 | Second derivative action lawsuit filed (Andrev v. Lebovits, et al.). |
| 2024-02-23 | Submitted SPA request to FDA for planned Phase 3b clinical trial of NurOwn for ALS. |
| 2024-02-25 | Presented compliance plan to Nasdaq Hearing Panel. |
| 2024-02-28 | Dr. Stacy Lindborg, former Co-Chief Executive Officer, provided a corporate update at 17th Annual European Life Sciences CEO Forum. |
| 2024-03-04 | Dr. Bob Dagher presented scientific poster on Phase 3b trial design at 2024 Muscular Dystrophy Association Clinical and Scientific Conference. |
| 2024-03-21 | Third derivative action lawsuit filed (Holtzman v. Lebovits, et al.). |
| 2024-03-25 | Received letter from Nasdaq Hearing Panel granting extension to regain compliance until June 30, 2025. |
| 2024-04-01 | Amended Complaint filed in Securities Action, adding former officer as defendant. |
| 2024-04-02 | Entered into Amendment No. 1 to New Distribution Agreement, Leerink Partners ceased to be an agent. |
| 2024-04-09 | Received written agreement from FDA, under a SPA, on the design for a Phase 3b trial of NurOwn in ALS. |
| 2024-04-12 | Fourth derivative action lawsuit filed (Hamby v. Lebovits, et al.). |
| 2024-04-25 | Court consolidated Derivative Actions into Consolidated Derivative Action. |
| 2024-05-31 | Company and individual defendants moved to dismiss Amended Complaint in Securities Action. |
| 2024-06-26 | Reached alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of NurOwn Phase 3b clinical trial. |
| 2024-06-27 | Entered into Securities Purchase Agreement for sale of 527,918 shares, pre-funded warrants, and unregistered warrants for $4.0 million gross proceeds. |
| 2024-06-28 | Offering closed for shares and warrants. |
| 2024-07-31 | Plaintiffs opposed motion to dismiss in Securities Action. |
| 2024-09-16 | Stockholders approved Amendment No. 4 to 2014 U.S. Plan and 2014 Global Option Plan. |
| 2024-09-17 | Company and individual defendants filed reply in support of motion to dismiss in Securities Action. |
| 2024-09-30 | Effected one-for-fifteen reverse stock split. |
| 2024-11-04 | Entered into loan agreement with a related party for $120,000. |
| 2024-11-22 | 3D Communications, LLC filed breach of contract lawsuit against the Company. |
| 2024-12-03 | Received Notice of Allowance from USPTO for exosome technology patent application. |
| 2024-12-15 | Entered into short-term loan agreement with a third-party lender for $180,000. |
| 2024-12-26 | Announced European grant for NurOwn, alongside Australian and Israeli allowances for NurOwn exosomes. |
| 2025-01-30 | Entered into short-term loan agreement with a third-party lender for $750,000. |
| 2025-03-06 | Entered into short-term loan agreement with a third-party lender for $100,000. |
| 2025-03-13 | Entered into short-term loan agreement with a third-party lender for $50,000. |
| 2025-03-31 | Entered into inducement offer with a holder to exercise existing warrants. |
| 2025-04-01 | Transactions under Warrant Inducement Agreement closed. |
| 2025-04-06 | March 13, 2025 loan repaid in full. |
| 2025-04-10 | Announced submission of an Investigational New Drug (IND) amendment to FDA for NurOwn in ALS. |
| 2025-05-06 | Remaining balance of 657,383 shares from Warrant Inducement Agreement issued. |
| 2025-05-08 | Bob Dagher presented new pharmacogenomic data on NurOwn at ISCT 2025 Annual Meeting. |
| 2025-05-13 | Participated in 4th Annual ALS Drug Development Summit. |
| 2025-05-19 | Announced FDA cleared initiation of Phase 3b clinical trial of NurOwn for ALS. |
| 2025-05-20 | January 30, 2025 loan repaid in full. |
| 2025-05-21 | November 4, 2024 and December 15, 2024 loans repaid in full. |
| 2025-05-27 | Signed Letter of Intent (LOI) with Minaris Advanced Therapies for NurOwn manufacturing. |
| 2025-06-16 | Announced new survival data from 10 participants in Expanded Access Program (EAP) for NurOwn in ALS. |
| 2025-06-25 | Held 2025 Annual Meeting of Stockholders, approved amendments to 2014 Plans to increase shared pool of shares. |
| 2025-06-27 | Amended pleadings due by this date in 3D Communications, LLC lawsuit. |
| 2025-07-08 | Acknowledged FDA consideration of a Citizen Petition requesting new review of NurOwn data. |
| 2025-07-17 | Received delisting notification from Nasdaq; announced delisting. |
| 2025-07-18 | Trading of common stock on Nasdaq suspended; began trading on OTCQB Venture Market. |
| 2025-08-11 | Number of shares outstanding of Common Stock was 10,376,109. |
| 2025-08-14 | Date of filing of this 10-Q report. |
| 2025-10-31 | Fact discovery to be completed by this date in 3D Communications, LLC lawsuit. |
| 2026-01-30 | Dispositive motions due by this date in 3D Communications, LLC lawsuit. |
| 2026-03-06 | Maturity date for $100,000 short-term loan. |
Recommendation
sellThe Nasdaq delisting is a significant negative event, severely impacting liquidity and investor confidence. While the FDA's SPA agreement for the Phase 3b ALS trial is a positive step, the prior overwhelming advisory committee vote against NurOwn's effectiveness and the withdrawal of the BLA indicate substantial clinical risk. The company continues to incur significant operating losses, has an accumulated deficit, and explicitly states a need for 'substantial additional financing' with no assurance of obtaining it on favorable terms. The identified material weakness in internal controls and multiple ongoing shareholder lawsuits further compound the operational and legal risks. Given these combined factors, the investment profile is highly speculative with significant downside risk, warranting a 'sell' recommendation for risk-averse investors and a cautious approach for others.
Keywords
Brainstorm Cell Therapeutics, BCLI, NurOwn, ALS, Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Cell Therapy, Biotechnology, SEC Filing, 10-Q, Clinical Trials, FDA, Orphan Drug, Fast Track, OTCQB, Nasdaq Delisting, Financial Results, Exosomes, PMS, Alzheimer's Disease, Capital Raise, Legal Proceedings, Internal Controls
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.